Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Antibodies is a leading open-access journal published by MDPI since 2012, focusing on the dynamic and rapidly evolving field of immunology and drug discovery. With an E-ISSN of 2073-4468, this esteemed journal aims to provide a platform for the dissemination of high-quality research on all aspects of antibody research, including novel therapeutic strategies, diagnostic applications, and the molecular mechanisms of immune responses. With an impressive portfolio reflecting its standing, Antibodies boasts a 2023 category quartile ranking of Q1 in Drug Discovery and Q2 in both Immunology and Immunology and Allergy. This positions the journal prominently within its field, further underscored by its Scopus rankings that illustrate its influence and relevance, including a rank of #46 out of 157 in Drug Discovery. As a fully open-access journal, Antibodies ensures that groundbreaking research is readily available to a diverse audience, enhancing the collaborative efforts in the scientific community. The journal's headquarters in beautiful Basel, Switzerland, is a testament to its commitment to maintaining high standards of academic excellence while fostering innovation and knowledge exchange among researchers, professionals, and students worldwide.

Bioanalysis is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of analytical and clinical biochemistry. Established in 2009, this journal has become a pivotal platform for high-quality, peer-reviewed research that explores innovative techniques in bioanalytical sciences, appealing to researchers, professionals, and students alike. With an impressive impact factor and ranked in the Q2 and Q3 quartiles across various categories, including Clinical Biochemistry and Pharmacology, Toxicology and Pharmaceutics, Bioanalysis serves as an essential resource for the latest developments in the interdisciplinary aspects of medicine and laboratory technology. While it does not currently offer open access, the journal is indexed in Scopus, ensuring visibility and accessibility to a global audience. The publication's commitment to enhancing knowledge in this vital area of research underscores its significance in fostering advancements that can lead to improved healthcare outcomes.

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

NATURE BIOTECHNOLOGY, an esteemed journal published by NATURE PORTFOLIO, stands at the forefront of innovation in biotechnological research since its inception in 1989. With an impressive impact factor reflecting its preeminent status—ranked in the Q1 quartile across multiple categories including Applied Microbiology, Bioengineering, Biomedical Engineering, Biotechnology, and Molecular Medicine—this journal is a pivotal resource for researchers and professionals aiming to advance the boundaries of biotechnology. The journal is highly regarded, boasting Scopus rankings in the 99th percentile within its categories. NATURE BIOTECHNOLOGY provides a platform for disseminating cutting-edge findings, with open access options that enhance the visibility and accessibility of its content to a global audience. The scope of the journal encapsulates a diverse range of topics from genetic engineering to pharmaceutical developments, ensuring comprehensive coverage of emerging biotechnological advances. As the field continues to evolve, NATURE BIOTECHNOLOGY remains committed to publishing groundbreaking research that shapes the future of science and industry.

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

MOLECULAR BIOTECHNOLOGY, published by SPRINGERNATURE, is a pivotal journal in the fields of applied microbiology, molecular biology, biochemistry, and biotechnology. Since its inception in 1994, the journal has aimed to disseminate high-quality research that explores the intersection of molecular biology and technology, fostering advancements in biotechnology applications. With an ISSN of 1073-6085 and an E-ISSN of 1559-0305, it has established itself as a significant contributor to the scientific community, currently holding a Q3 ranking across multiple categories including Applied Microbiology & Biotechnology and Biochemistry in the 2023 metrics. Although not an open access publication, the journal remains accessible through various institutional subscriptions, providing valuable insights and findings to researchers and professionals. Given its ongoing commitment to quality and relevance, MOLECULAR BIOTECHNOLOGY serves as an essential resource for those involved in cutting-edge research and innovation in molecular biotechnology and related disciplines.